<DOC>
	<DOCNO>NCT02217917</DOCNO>
	<brief_summary>This 2 part study design provide initial assessment safety , tolerability , PK rivipansel , follow single ascend ( Part 1 ) multiple ascend dosing ( Part 2 ) give subcutaneously rHuPH20 , healthy subject . Part 1 study conduct use cross-over design Part 2 study conduct use parallel design .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics Subcutaneous Rivipansel With rHuPH20 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject nonchildbearing potential age 18 55 year , inclusive . Body Mass Index 17.5 30.5 kg/m2 body weight &gt; 50 kg Screening . Normal skin without potentially obscure feature area intend infusion . Subjects willing defer receive prophylactic immunization ( eg , influenza pneumococcal vaccine ) study . Evidence personally sign date informed consent document indicate subject legally acceptable representative inform pertinent aspect study Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . History recent major surgery ( within 3 month screen ) . Serious infection within 1 month screening . Subjects chronic skin condition may interfere assessment emergent safety data . A positive urine drug screen . Known sensitivity hyaluronidase . History hepatitis positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( HBcAb ) hepatitis C antibody ( HCV ) . Unwilling unable comply Lifestyle Guidelines describe protocol . Subjects investigational site staff member directly involved conduct study family member , site staff member otherwise supervised Investigator , subject Pfizer employee directly involve conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Single ascend dose</keyword>
	<keyword>Multiple ascend dose</keyword>
</DOC>